CDKN2A and prostate cancer: For example, in the drug sensitivity experiment, IL6, which could be the SL partner gene of CDKN2A, RB1, STK11 and TP53, was a specific anticancer drug target in the prostate cancer DU-145 cell line when targeted by VX-70237.